ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...

The FDA has accepted for review the BLA for nanoencapsulated sirolimus plus pegadricase in the treatment of uncontrolled gout.

The gout market is poised for steady growth, driven by the rising prevalence of the disease, increasing awareness, and the launch of novel therapies such as AR-882, Epaminurad, XNW3009, XRx-026, ...